5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
India
Nasopharyngeal Cancer Market - Growth, Trends, and Forecast (2020 - 2025)
The market is segmented by Treatment Type (Chemotherapy, Radiation Therapy, Others) and Geography
- ABOUT THIS REPORT
- Market Snapshot
- Market Overview
- Scope of the Report
- Key Market Trends
- Competitive Landscape
- Major Players
- TABLE OF CONTENTS
Market Snapshot
Study Period:
2016-2024
Base Year:
2019
Fastest Growing Market:
Asia Pacific
Largest Market:
North America
Major Players:
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
Market Overview
Global Nasopharyngeal Cancer market is expected to witness a steady CAGR of 2.2% during the forecast period. Certain factors that are driving the market growth include a moderate rise in the burden of the disease and growing awareness towards diagnosis and treatment.
There is a growing awareness of the diagnosis and treatment of nasopharyngeal cancer (NPC). Traditionally the public perception regarding nasopharyngeal cancer was very weak due to lack of government initiatives and low incidence rate of the disease. But, the rise in the number of NPC patients in North America region has changed this scenario. In the United States, nasopharyngeal carcinoma (NPC) is a rare malignancy of the upper digestive tract and has an incidence of less than 1 per 100,000. However, this disease has a well-documented regional and ethnic distribution such that individuals of Southern Chinese and Southeast Asian descent are up to 20-40 times more likely to develop NPC than individuals of European ethnicity. To increase community awareness for ethnicities, which are predisposed to nasopharyngeal cancer, various primary healthcare centers have started awareness campaigns to increase the awareness of NPC. Consequently, greater adoption of NPC diagnosis and treatment is being witnessed, which is driving the growth of the global nasopharyngeal cancer market.
Scope of the Report
Nasopharyngeal cancer is a disease in which malignant cancer cells form in the tissues of the nasopharynx (the upper part of throat behind the nose). Among many factors, ethnic background along with being exposed to the Epstein-Barr virus can affect the risk of nasopharyngeal cancer.
| Treatment Type | |
| Chemotherapy | |
| Radiation Therapy | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Report scope can be customized per your requirements. Click here.
Key Market Trends
Radiation Therapy is Expected to Hold Significant Market Share in the Treatment Type Segment
Radiation therapy forms the primary modality of treatment in nasopharyngeal cancer. It is closely followed by chemotherapy in terms of both market share and use-case in patients. Newer and advanced modalities of nasopharyngeal cancer treatment include a combination of both radiotherapy and chemotherapy techniques. These treatment modalities are still in early clinical phases and will make a commercial appearance late during the end of the forecast period or maybe even after that.
To understand key trends, Download Sample Report
Asia Pacific Dominates the Market and Expected to do Same in the Forecasted Period
In Asia pacific, nasopharyngeal cancer is one of the most common cancers in the head and neck areas. Men are two to three times more likely to develop it than women. The peak age of incidence is between 50 and 60 years. Nasopharyngeal cancer is generally more common in Southeast Asia. The five countries with the highest incidence of nasopharyngeal cancer in the world were China, Indonesia, Vietnam, India and Malaysia, respectively. The standard incidence of nasopharyngeal cancer in the world was 1.2 per 100,000 (in men 1.7 per 100,000; in women, 0.7 per 100,000).
To understand geography trends, Download Sample Report.
Competitive Landscape
The global Nasopharyngeal Cancermarket is highly competitive and consists of a few major players. Companies like Biocon, Bristol Myers Squibb, Cyclacel Pharmaceuticals, F. Hoffman La-Roche, Merck & Co., Novartis, Pfizer, among others, hold the substantial market share in the Nasopharyngeal Cancermarket.
Table Of Contents
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of the Cancer Disease
4.2.2 Growing Awareness Towards Diagnosis and Treatment
4.3 Market Restraints
4.3.1 High Cost of the Treatment
4.3.2 Side Effects Associated with the Disease
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Treatment Type
5.1.1 Chemotherapy
5.1.2 Radiation Therapy
5.1.3 Others
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biocon Limited
6.1.2 Bristol Myers Squibb
6.1.3 Cyclacel Pharmaceuticals
6.1.4 F. Hoffman La-Roche
6.1.5 Merck & Co., Inc.
6.1.6 Novartis AG
6.1.7 Pfizer, Inc.
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
LINKS
JOIN US
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination.
Interested? Please email us
[email protected]© 2020. All Rights Reserved to Mordor Intelligence.